TR201819789T4 - Kanser tedavisine yönelik gemsitabin ve kombine telomeraz inhibitörü. - Google Patents
Kanser tedavisine yönelik gemsitabin ve kombine telomeraz inhibitörü. Download PDFInfo
- Publication number
- TR201819789T4 TR201819789T4 TR2018/19789T TR201819789T TR201819789T4 TR 201819789 T4 TR201819789 T4 TR 201819789T4 TR 2018/19789 T TR2018/19789 T TR 2018/19789T TR 201819789 T TR201819789 T TR 201819789T TR 201819789 T4 TR201819789 T4 TR 201819789T4
- Authority
- TR
- Turkey
- Prior art keywords
- gemcitabine
- telomerase inhibitor
- combined
- cancer treatment
- cancer
- Prior art date
Links
- 229940123582 Telomerase inhibitor Drugs 0.000 title abstract 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title abstract 3
- 229960005277 gemcitabine Drugs 0.000 title abstract 3
- 239000003277 telomerase inhibitor Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002301 combined effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Abstract
Kanser hücrelerinin proliferasyonunun engellenmesine yönelik bir yöntem ve kit, bir gemsitabin ve bir telomeraz inhibitörün bir kombinasyonuna bağlı olarak açıklanır. Kanser terapisinde kullanıldığında, kombinasyon halinde iki bileşik, tek başına gemsitabin veya tek başına telomeraz inhibitörü ile elde edilen anti-kanser tedavi efikasitesini pekiştirir. Tercihen efikasite, yan etkilerin minimum şiddetlenmesi ile ayrı ajanların kombine edilmiş etkilerine göre doğada supra aditif veya sinerjistiktir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85558306P | 2006-10-30 | 2006-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201819789T4 true TR201819789T4 (tr) | 2019-01-21 |
Family
ID=39344866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2018/19789T TR201819789T4 (tr) | 2006-10-30 | 2007-10-30 | Kanser tedavisine yönelik gemsitabin ve kombine telomeraz inhibitörü. |
Country Status (13)
Country | Link |
---|---|
US (1) | US7989428B2 (tr) |
EP (3) | EP3494975A1 (tr) |
CY (1) | CY1121244T1 (tr) |
DK (2) | DK2101789T3 (tr) |
ES (2) | ES2533264T3 (tr) |
HK (1) | HK1212612A1 (tr) |
HU (1) | HUE041448T2 (tr) |
LT (1) | LT2898887T (tr) |
PL (2) | PL2101789T3 (tr) |
PT (2) | PT2101789E (tr) |
SI (2) | SI2101789T1 (tr) |
TR (1) | TR201819789T4 (tr) |
WO (1) | WO2008054711A2 (tr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06002660A (es) | 2003-09-09 | 2006-09-04 | Geron Corp | Oligonucleotidos modificados para inhibicion de telomerasa. |
WO2008112129A2 (en) * | 2007-03-09 | 2008-09-18 | Geron Corporation | Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors |
US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
LT3065828T (lt) | 2013-11-06 | 2019-04-10 | Mayo Foundation For Medical Education And Research | Būdai ir medžiagos, skirti hematologinių piktybinių būklių gydymui |
JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
WO2017165675A1 (en) * | 2016-03-24 | 2017-09-28 | The Board Of Regents Of The University Of Texas System | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds |
EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
US7067497B2 (en) * | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6444650B1 (en) * | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
CA2274586A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
US6995145B1 (en) * | 1999-06-04 | 2006-02-07 | Au Jessie L-S | Methods and compositions for modulating drug activity through telomere damage |
DE60038495T2 (de) * | 1999-09-10 | 2009-04-09 | Geron Corp., Menlo Park | Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
ES2716528T3 (es) | 2003-06-23 | 2019-06-13 | Telomerase Activation Sciences Inc | Composiciones para aumentar la actividad telomerasa |
MXPA06002660A (es) * | 2003-09-09 | 2006-09-04 | Geron Corp | Oligonucleotidos modificados para inhibicion de telomerasa. |
PL3296312T3 (pl) | 2004-07-02 | 2021-10-25 | Geron Corporation | Synteza chronionych monomerów 3'-amino-5'-amidofosforanonukleozydowych |
WO2006113426A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and tubulin activities |
WO2006113470A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
WO2006124904A2 (en) | 2005-05-16 | 2006-11-23 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and hsp90 activities |
WO2008112129A2 (en) | 2007-03-09 | 2008-09-18 | Geron Corporation | Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors |
-
2007
- 2007-10-30 DK DK07867297.9T patent/DK2101789T3/en active
- 2007-10-30 EP EP18196347.1A patent/EP3494975A1/en active Pending
- 2007-10-30 PL PL07867297T patent/PL2101789T3/pl unknown
- 2007-10-30 SI SI200731627T patent/SI2101789T1/sl unknown
- 2007-10-30 ES ES07867297.9T patent/ES2533264T3/es active Active
- 2007-10-30 DK DK14198829.5T patent/DK2898887T3/en active
- 2007-10-30 ES ES14198829T patent/ES2696828T3/es active Active
- 2007-10-30 PT PT07867297T patent/PT2101789E/pt unknown
- 2007-10-30 US US12/446,931 patent/US7989428B2/en active Active
- 2007-10-30 EP EP14198829.5A patent/EP2898887B1/en active Active
- 2007-10-30 HU HUE14198829A patent/HUE041448T2/hu unknown
- 2007-10-30 LT LTEP14198829.5T patent/LT2898887T/lt unknown
- 2007-10-30 PL PL14198829T patent/PL2898887T3/pl unknown
- 2007-10-30 WO PCT/US2007/022850 patent/WO2008054711A2/en active Application Filing
- 2007-10-30 EP EP07867297.9A patent/EP2101789B1/en active Active
- 2007-10-30 TR TR2018/19789T patent/TR201819789T4/tr unknown
- 2007-10-30 PT PT14198829T patent/PT2898887T/pt unknown
- 2007-10-30 SI SI200732076T patent/SI2898887T1/sl unknown
-
2016
- 2016-01-20 HK HK16100587.1A patent/HK1212612A1/zh unknown
-
2018
- 2018-11-22 CY CY20181101238T patent/CY1121244T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HUE041448T2 (hu) | 2019-05-28 |
WO2008054711A3 (en) | 2008-12-24 |
EP2101789A2 (en) | 2009-09-23 |
ES2696828T3 (es) | 2019-01-18 |
SI2898887T1 (sl) | 2019-01-31 |
US7989428B2 (en) | 2011-08-02 |
LT2898887T (lt) | 2018-11-12 |
EP2101789A4 (en) | 2010-11-10 |
PT2101789E (pt) | 2015-03-24 |
PT2898887T (pt) | 2018-12-20 |
EP2898887A1 (en) | 2015-07-29 |
PL2898887T3 (pl) | 2019-05-31 |
EP2898887B1 (en) | 2018-09-26 |
WO2008054711A2 (en) | 2008-05-08 |
PL2101789T3 (pl) | 2015-05-29 |
HK1212612A1 (zh) | 2016-06-17 |
US20100016407A1 (en) | 2010-01-21 |
DK2101789T3 (en) | 2015-03-23 |
SI2101789T1 (sl) | 2015-04-30 |
EP3494975A1 (en) | 2019-06-12 |
EP2101789B1 (en) | 2014-12-31 |
ES2533264T3 (es) | 2015-04-08 |
DK2898887T3 (en) | 2019-01-07 |
CY1121244T1 (el) | 2020-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201819789T4 (tr) | Kanser tedavisine yönelik gemsitabin ve kombine telomeraz inhibitörü. | |
EP1876893A4 (en) | TREATMENT OF CANCER BY THE COMBINED INHIBITION OF PROTEASOME AND TELOMERASE ACTIVITIES | |
CR11486A (es) | Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
AR048819A1 (es) | Metodos sinergicos y composiciones para el tratamiento del cancer | |
CY1118933T1 (el) | Anti-cxcr1 συνθεσεις και μεθοδοι | |
ME00936B (me) | Postupci liječenja kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa | |
BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
BRPI0517135A (pt) | composições e métodos para tratar doenças neoplásticas | |
TW200738263A (en) | ANG2 and VEGF inhibitor combinations | |
MX2010006154A (es) | Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa. | |
TW200501960A (en) | Synergistic kits and compositions for treating cancer | |
EA201500417A1 (ru) | Композиции антагонистов pd-1 и способы применения | |
GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
TR201910825T4 (tr) | Yemek borusu rahatsizliklarini tedavi̇ etmek i̇çi̇n yöntemler ve bi̇leşi̇mler | |
JO3262B1 (ar) | توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان | |
EA200900691A1 (ru) | Применение ингибиторов iap для лечения острого миелоидного лейкоза | |
BR112012022243A2 (pt) | terapias inibidoras de autografia baseadas em tioxantona para tratar câncer | |
WO2006081371A3 (en) | Combination therapy with triterpenoid compounds and proteasome inhibitors | |
WO2006124904A3 (en) | Cancer treatment by combined inhibition of telomerase and hsp90 activities | |
WO2006113426A3 (en) | Cancer treatment by combined inhibition of telomerase and tubulin activities | |
MXPA05011213A (es) | Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia. | |
BRPI0716992A2 (pt) | inibidores da histona desacetilase com atividade combinada sobre as histona desacetilases classe i e classe iib em combinaÇço com inibidores da proteossoma | |
PH12014501454B1 (en) | Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents |